HIP
EGRX

Hatteras Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Hatteras Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-21,770
Closed -$882K – 70
2016
Q1 		$882K Buy
21,770
+17,230
+380% +$1.09M 2.41% 11
2015
Q4 		$403K Buy
+4,540
New +$358K 0.53% 57

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Hatteras Investment Partners's EGRX Position: Q2 2016 in Review

Hatteras Investment Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2016, closing a stake of 21,770 shares — an estimated $882K sold.

Hatteras Investment Partners first reported a position in EGRX in Q4 2015 and held it in 2 quarters. The position peaked at $882K in Q1 2016. 116 funds tracked by Wall St. Rank hold EGRX as of Q2 2016.

  • Hatteras Investment Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Hatteras Investment Partners sold 21,770 Eagle Pharmaceuticals, Inc. shares in Q2 2016, an estimated $882K.
  • Hatteras Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • Hatteras Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $882K in Q1 2016.
  • 116 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2016.

Based on Hatteras Investment Partners's 13F filing for Q2 2016, filed 15 Aug 2016.